Shionogi & Co., Ltd. – Product Pipeline Review – 2013

Publisher Name :
Date: 31-Jul-2013
No. of pages: 78
Inquire Before Buying

Shionogi & Co., Ltd. – Product Pipeline Review – 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Shionogi & Co., Ltd. – Product Pipeline Review – 2013″ provides data on the Shionogi & Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Shionogi & Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Shionogi & Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Shionogi & Co., Ltd. – Brief Shionogi & Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Shionogi & Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Shionogi & Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Shionogi & Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Shionogi & Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Shionogi & Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Shionogi & Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Shionogi & Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Shionogi & Co., Ltd. and identify potential opportunities in those areas.

Shionogi & Co., Ltd. – Product Pipeline Review – 2013

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Shionogi & Co., Ltd. Snapshot 8
Shionogi & Co., Ltd. Overview 8
Key Information 8
Key Facts 8
Shionogi & Co., Ltd. - Research and Development Overview 9
Key Therapeutic Areas 9
Shionogi & Co., Ltd. - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Shionogi & Co., Ltd. - Pipeline Products Glance 17
Shionogi & Co., Ltd. - Late Stage Pipeline 17
Phase III Products/Combination Treatment Modalities 17
Shionogi & Co., Ltd. Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Shionogi & Co., Ltd. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Shionogi & Co., Ltd. - Drug Profiles 22
(irbesartan + trichlormethiazide) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(lidocaine + prilocaine) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
39-f 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Actair 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Benzimidazole Derivative 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Beta-Secretase Inhibitor 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Compound-18e 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
doripenem 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
duloxetine hydrochloride DR 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
guanfacine hydrochloride ER 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
interferon gamma-1a 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Japanese Cedar Pollen Tablet 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
lisdexamfetamine dimesylate 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lusutrombopag 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
naldemedine 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ospemifene 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
oxycodone hydrochloride 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
P2X3 Receptor Antagonist 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Peptide Cocktail Vaccine 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
prednisolone acetate 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
S-117957 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
S-120083 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
S-222611 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
S-234462 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
S-288310 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
S-488210 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
S-488410 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
S-555739 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
S-556971 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
S-646240 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
S-649266 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
S-707106 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
velneperit 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Shionogi & Co., Ltd. - Pipeline Analysis 55
Shionogi & Co., Ltd. - Pipeline Products by Therapeutic Class 55
Shionogi & Co., Ltd. - Pipeline Products By Target 59
Shionogi & Co., Ltd. - Pipeline Products by Route of Administration 60
Shionogi & Co., Ltd. - Pipeline Products By Mechanism of Action 61
Shionogi & Co., Ltd. - Recent Pipeline Updates 63
Shionogi & Co., Ltd. - Dormant Projects 69
Shionogi & Co., Ltd. - Discontinued Pipeline Products 70
Discontinued Pipeline Product Profiles 70
ADX-415 70
clonidine hydrochloride 70
doripenem 70
lusutrombopag 71
S-444823 71
S-5751 71
S-777469 71
S-8510 71
teceleukin 72
velneperit 72
Shionogi & Co., Ltd. - Company Statement 73
Shionogi & Co., Ltd. - Locations And Subsidiaries 74
Head Office 74
Other Locations & Subsidiaries 74
Shionogi & Co., Ltd. - Key Manufacturing Facilities 76
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78

List of Tables
Shionogi & Co., Ltd., Key Information 8
Shionogi & Co., Ltd., Key Facts 8
Shionogi & Co., Ltd. - Pipeline by Indication, 2013 12
Shionogi & Co., Ltd. - Pipeline by Stage of Development, 2013 14
Shionogi & Co., Ltd. - Monotherapy Products in Pipeline, 2013 15
Shionogi & Co., Ltd. - Combination Treatment Modalities in Pipeline, 2013 16
Shionogi & Co., Ltd. - Phase III, 2013 17
Shionogi & Co., Ltd. - Phase II, 2013 18
Shionogi & Co., Ltd. - Phase I, 2013 19
Shionogi & Co., Ltd. - Preclinical, 2013 20
Shionogi & Co., Ltd. - Discovery, 2013 21
Shionogi & Co., Ltd. - Pipeline By Therapeutic Class, 2013 56
Shionogi & Co., Ltd. - Pipeline By Target, 2013 59
Shionogi & Co., Ltd. - Pipeline By Route of Administration, 2013 60
Shionogi & Co., Ltd. - Pipeline Products By Mechanism of Action, 2013 61
Shionogi & Co., Ltd. - Recent Pipeline Updates, 2013 63
Shionogi & Co., Ltd. - Dormant Developmental Projects,2013 69
Shionogi & Co., Ltd. - Discontinued Pipeline Products, 2013 70
Shionogi & Co., Ltd., Other Locations 74
Shionogi & Co., Ltd., Subsidiaries 75
Shionogi & Co., Ltd., Key Manufacturing Facilities 76

List of Figures
Shionogi & Co., Ltd. - Pipeline by Indication, 2013 11
Shionogi & Co., Ltd. - Pipeline by Stage of Development, 2013 14
Shionogi & Co., Ltd. - Monotherapy Products in Pipeline, 2013 15
Shionogi & Co., Ltd. - Combination Treatment Modalities in Pipeline, 2013 16
Shionogi & Co., Ltd. - Pipeline By Therapeutic Class, 2013 55
Shionogi & Co., Ltd. - Pipeline By Route of Administration, 2013 60
Shionogi & Co., Ltd. - Pipeline Products By Mechanism of Action, 2013 61
  • China Commercial Vehicle Industry
    Commercial vehicle are usually large trucks, buses or vans used to transport people,  goods and material. China is one of the nations that contributes to over 50% of commercial vehicle production. The industry has grown in leaps and bounds over the couple of years. Even though the growth rates aren’t as impressive as two years [...]
  • The Prospective Market of Drug Eluting Stents
    Drug Eluting Stents are the recent development that’s are now being used frequently for curing narrowed coronary arteries. These stents help to keep the artery open and supply drugs at regular intervals preventing any further obstruction. The stents are usually small scaffolds of wire and are placed in the artery. This has been a welcome [...]
  • Anaesthesia Machine Industry is Flourishing due to an Extensive Customer Base with Therapeutic Needs
    The Anaesthesia Machine Industry comprises of the manufacturers and users of Anaesthesia Machines which are basically workstations or units that assist a person to administer Anaesthesia on the other. It includes plug & play Anaesthesia delivery units (ADUs). The industry also comprises of the various accessories like monitors and information systems and support services involved [...]
  • The Need for an Electric Cars Boosts The Lithium Sulfate Market
    Lithium is a highly demanded material. The popularity of this metal is primarily due to the characteristics of this metal and its compounds. Some of the characteristics of this material are that it has the highest electrochemical potential of all metals, a very high co-efficient of thermal expansion, acting as a viscosity modifier in melts, [...]
  • Tire Roller Industry
    Tire roller is one of the most popular equipment used in the construction industry. A tire roller offers multiple services from building highways, industrial sites, binder courses, wear courses and many more. Tire rollers come with different features like easy adjustment of tyres, flexible ballast, oscillating tires, etc. that facilitates in doing a particular work. [...]
  • The Oil Drilling Rig Industry
  • The Oil Drilling Rig Industry is characterized with a few typical work specific to this industry only. The work begins with the search for new oil basins or construction of wells. During this time the services of drilling contractors and …

  • HER2-Negative Breast Cancer’s Therapeutic Market
  • HER2-Negative Breast Cancer is the most common form of cancer occurring in women. The long term survival of patients diagnosed with HER2-Negative Breast Cancer depends solely on its early detection as till now there is no medicine that can cure …

  • The Market of Plate Heat Exchanger
  • Plate heat exchanger is not only very useful but its also easy to maintain, its compact design makes it more efficient, the product is highly cost-efficient and also the materials of this product are easily available. There are some limitations …

  • The Industry of Binding Machines
  • Binding of books and papers is one of the most important aspect of buying and selling books and thus the demand of binding machines. There are different kinds of binding machines available in the market. The binding type determines the …

  • The Boom In Women Infertility Market
  • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • Latvia Pharmaceuticals and Healthcare Report Q3 2015
    Published: 27-May-2015        Price: US $1295 Onwards        Pages: 107
    BMI View: Latvia's pharmaceutical market offers stable growth, at least in local currency terms, although the country will continue to present a modest opportunity to larger multinational companies on account of its relatively small market size. Meanwhile, tensions between Ukraine and Russia are creating challenges for local manufacturers that have focused on exports to Russia and the Commonwealth of Independent States (CIS) region. Headline Expenditure Projections ? Pharmaceuticals: EUR313mn (U......
  • Lebanon Pharmaceuticals and Healthcare Report Q3 2015
    Published: 27-May-2015        Price: US $1295 Onwards        Pages: 116
    BMI View: Lebanon's drug pricing legislation will keep medicine prices among the lowest in the Middle East region. In addition to this, the government's commitment to achieving universal access to healthcare will drive growth in the pharmaceutical market. Generic drug makers will see strong growth following the implementation of a unified prescription form, as part of the National Social Security Fund. However, political instability and pressures faced by the influx of Syrian refugees will conti......
  • Romania Pharmaceuticals and Healthcare Report Q3 2015
    Published: 27-May-2015        Price: US $1295 Onwards        Pages: 118
    BMI View: We expect growth in pharmaceutical sales in 2015 to be primarily driven by Romania's improving macroeconomic outlook and a positive consumer story. We note that local regulatory factors such as revenue taxes will continue to present obstacles to growth. Rising clawback taxes and continued price cuts will be negative for the prescription drugs, hurting Romania's attractiveness to multinational drugmakers. Headline Expenditure Projections ? Pharmaceuticals: RON14.17bn (USD4.28bn) in 2014......
  • Singapore Pharmaceuticals and Healthcare Report Q3 2015
    Published: 27-May-2015        Price: US $1295 Onwards        Pages: 135
    BMI View: Singapore's healthcare system will continue to evolve, led by changes from the government. This is reflected in the distinct shift in policy that will see the authorities raising its contribution to the country's total healthcare spending. In addition, Singapore's medical system will be increasingly geared towards the health needs of the elderly with additional resources in the 2015 budget channelled towards the treatment of dementia. This will create strong commercial prospects for ph......
  • Taiwan Pharmaceuticals and Healthcare Report Q3 2015
    Published: 27-May-2015        Price: US $1295 Onwards        Pages: 136
    BMI View: The Taiwanese pharmaceutical market will continue to be highly attractive for multinational drugmakers. As the seventh largest market in the Asia Pacific, the country's commercial opportunities are further reinforced by its high pharmaceutical spending per capita and robust medical infrastructure. In addition, Taiwan has a favourable disease profile as the growing burden imposed by chronic diseases will drive up demand for pharmaceutical products. Headline Expenditure Projections ? Pha......
  • Uganda Pharmaceuticals and Healthcare Report Q3 2015
    Published: 27-May-2015        Price: US $1295 Onwards        Pages: 64
    BMI View: Recently Civil society organisations in Uganda have urged the country's legislators to reject the proposed budget reductions by 4% for the health sector for FY15/16. The reduction would severely affect the efforts to stop maternal, new born and child mortality and also access to indispensable health services, the CSOs noted. On a more positive note, the country's economic prospects improved lately as well with the GDP forecasts being revised upwards. This allows us to expect that Ugand......
  • Bulgaria Pharmaceuticals and Healthcare Report Q3 2015
    Published: 27-May-2015        Price: US $1295 Onwards        Pages: 105
    BMI View: Pharmaceutical manufacturers will face increased pricing pressures from the National Health Insurance Fund (NHIF) as we expect a wave of cost-containment measures to be adopted. The NHIF will leverage its purchasing power to reduce its runaway pharmaceutical expenditure, with negative implications for the sector's growth profile. We expect generic drug penetration to rise and patented drug sales to slow considerably as the NHIF rebalances its expenditures. Headline Expenditure Projecti......
  • Global Omega-3 Fish Oils Industry Report 2015
    Published: 26-May-2015        Price: US $2800 Onwards        Pages: 186
    This is a professional and in-depth study on the current state of the Omega-3 Fish Oils industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Omega-3 Fish Oils market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes an......
  • Global Omega-3 Industry Report 2015
    Published: 26-May-2015        Price: US $2800 Onwards        Pages: 176
    This is a professional and in-depth study on the current state of the Omega-3 industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Omega-3 market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures ar......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs